Meeting
2022 ASCO Annual Meeting
Durvalumab treatment initiation delays in patients with unresectable stage III non–small cell lung cancer treated at Veterans Health Administration facilities.
Authors
Paromita Datta
South Texas Veterans Health Care System, San Antonio, TX
Paromita Datta , Amanda Moore , Christopher R Frei , Kelly R Reveles , Lance Brannman , Ion Cotarla , Andrew Frankart , Tiernan Mulrooney , Munaf Alkadimi , Jennifer Whitehead , Kathleen Franklin , Renee Reichelderfer , Madison H. Williams , Ryan A. Williams , Sarah Allison Smith , Xavier Jones , Zohra Nooruddin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8556)
DOI
10.1200/JCO.2022.40.16_suppl.8556
Abstract #
8556
Poster Bd #
183
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Racial disparities in the clinical use of durvalumab for patients with stage III unresectable non–small cell lung cancer treated at Veterans Health Administration facilities.
First Author: Amanda Moore
Poster
2021 ASCO Quality Care Symposium
Durvalumab consolidation therapy following chemoradiotherapy among patients with unresectable stage III non-small cell lung cancer (NSCLC) treated in a U.S. community oncology network.
First Author: David Michael Waterhouse
Poster
2023 ASCO Quality Care Symposium
Management and treatment of patients (pts) with stage III unresected non-small cell lung cancer (NSCLC) at UPMC: A quality initiative by Integra Connect PrecisionQ.
First Author: Daniel P. Petro
Poster
2023 ASCO Annual Meeting
A phase I-III platform study evaluating the safety and efficacy of multiple therapies in patients with biomarker-defined locally advanced, unresectable stage III non–small-cell lung cancer (NSCLC).
First Author: Luis G. Paz-Ares